CN1868468A - 毛萼乙素在制药中的应用 - Google Patents
毛萼乙素在制药中的应用 Download PDFInfo
- Publication number
- CN1868468A CN1868468A CNA2005101100898A CN200510110089A CN1868468A CN 1868468 A CN1868468 A CN 1868468A CN A2005101100898 A CNA2005101100898 A CN A2005101100898A CN 200510110089 A CN200510110089 A CN 200510110089A CN 1868468 A CN1868468 A CN 1868468A
- Authority
- CN
- China
- Prior art keywords
- cell
- erib
- kasumi
- apoptosis
- eriocalyxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RTIKCEKESDRWAE-UHFFFAOYSA-N eriocalyxin B Natural products C=C1C(=O)C23CC1CCC2C12C(=O)C=CC(C)(C)C1C(O)C3(O)OC2 RTIKCEKESDRWAE-UHFFFAOYSA-N 0.000 claims abstract description 28
- RTIKCEKESDRWAE-UJVKWQRCSA-N eriocalyxin b Chemical compound C([C@@H]1C[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(=O)C=CC(C)(C)[C@H]1[C@H](O)[C@@]3(O)OC2 RTIKCEKESDRWAE-UJVKWQRCSA-N 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 16
- 208000011691 Burkitt lymphomas Diseases 0.000 claims abstract description 6
- 206010000830 Acute leukaemia Diseases 0.000 claims abstract description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 21
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 230000004927 fusion Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 3
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims description 3
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 153
- 108010057466 NF-kappa B Proteins 0.000 description 62
- 102000003945 NF-kappa B Human genes 0.000 description 62
- 230000006907 apoptotic process Effects 0.000 description 41
- 230000000694 effects Effects 0.000 description 36
- 230000001939 inductive effect Effects 0.000 description 35
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 29
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 29
- 102000003952 Caspase 3 Human genes 0.000 description 26
- 108090000397 Caspase 3 Proteins 0.000 description 26
- 102100023132 Transcription factor Jun Human genes 0.000 description 23
- 208000032839 leukemia Diseases 0.000 description 22
- 230000026731 phosphorylation Effects 0.000 description 21
- 238000006366 phosphorylation reaction Methods 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 19
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 18
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 18
- 108700000711 bcl-X Proteins 0.000 description 18
- 102000055104 bcl-X Human genes 0.000 description 18
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 17
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 17
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 16
- 238000001994 activation Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 230000004913 activation Effects 0.000 description 13
- 238000012545 processing Methods 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 12
- 102000055102 bcl-2-Associated X Human genes 0.000 description 12
- 108700000707 bcl-2-Associated X Proteins 0.000 description 12
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 10
- 210000004940 nucleus Anatomy 0.000 description 10
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 9
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 9
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 9
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 210000003470 mitochondria Anatomy 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 108090000672 Annexin A5 Proteins 0.000 description 8
- 102000004121 Annexin A5 Human genes 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 8
- 102100027584 Protein c-Fos Human genes 0.000 description 8
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 210000000805 cytoplasm Anatomy 0.000 description 8
- 102000011931 Nucleoproteins Human genes 0.000 description 7
- 108010061100 Nucleoproteins Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108010005774 beta-Galactosidase Proteins 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000005945 translocation Effects 0.000 description 5
- 230000004568 DNA-binding Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000000197 pyrolysis Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000554447 Isodon eriocalyx Species 0.000 description 3
- 241001646826 Isodon rubescens Species 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 230000006909 anti-apoptosis Effects 0.000 description 3
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 3
- 102000005936 beta-Galactosidase Human genes 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000010523 cascade reaction Methods 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
- 102000051485 Bcl-2 family Human genes 0.000 description 2
- 108700038897 Bcl-2 family Proteins 0.000 description 2
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010040476 FITC-annexin A5 Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002038 chemiluminescence detection Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- -1 diterpene compound Chemical class 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000006667 mitochondrial pathway Effects 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 229940124101 Caspase 3 inhibitor Drugs 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101001072488 Homo sapiens Golgi reassembly-stacking protein 1 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 102000008379 I-kappa B Proteins Human genes 0.000 description 1
- 108010021699 I-kappa B Proteins Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004430 Mapka Substances 0.000 description 1
- 101001000691 Medicago sativa Pectinesterase Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 101000907437 Mycoplasma hyopneumoniae (strain 232) Chaperone protein DnaK Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102100033103 NF-kappa-B inhibitor delta Human genes 0.000 description 1
- 101710115380 NF-kappa-B inhibitor delta Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102100036417 Synaptotagmin-1 Human genes 0.000 description 1
- 241000202349 Taxus brevifolia Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000009462 endogenous apoptosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ONVABDHFQKWOSV-HPUSYDDDSA-N ent-kaur-16-ene Chemical class C1C[C@H](C2)C(=C)C[C@@]32CC[C@@H]2C(C)(C)CCC[C@@]2(C)[C@@H]31 ONVABDHFQKWOSV-HPUSYDDDSA-N 0.000 description 1
- 229930183168 eriocalyxin Natural products 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000027829 mitochondrial depolarization Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 229910052957 realgar Inorganic materials 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims (6)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101100898A CN100370981C (zh) | 2005-11-07 | 2005-11-07 | 毛萼乙素在制药中的应用 |
EP06791205A EP1952811A4 (en) | 2005-11-07 | 2006-10-08 | USE OF ERIOCALYXIN B FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF LEUKEMIA |
US12/092,914 US20080300299A1 (en) | 2005-11-07 | 2006-10-08 | Application of Eriocalyxin B in the Manufacture of Medicaments For Treating Leukemia |
JP2008539213A JP2009514903A (ja) | 2005-11-07 | 2006-10-08 | 製薬におけるエリオカリキシンbの応用 |
PCT/CN2006/002623 WO2007051390A1 (fr) | 2005-11-07 | 2006-10-08 | Utilisation de l'eriocalyxine b pour la fabrication de medicaments destines au traitement de la leucemie |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101100898A CN100370981C (zh) | 2005-11-07 | 2005-11-07 | 毛萼乙素在制药中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1868468A true CN1868468A (zh) | 2006-11-29 |
CN100370981C CN100370981C (zh) | 2008-02-27 |
Family
ID=37442335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005101100898A Expired - Fee Related CN100370981C (zh) | 2005-11-07 | 2005-11-07 | 毛萼乙素在制药中的应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080300299A1 (zh) |
EP (1) | EP1952811A4 (zh) |
JP (1) | JP2009514903A (zh) |
CN (1) | CN100370981C (zh) |
WO (1) | WO2007051390A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101318965B (zh) * | 2008-07-18 | 2010-11-24 | 中国科学院昆明植物研究所 | 毛萼乙素结晶、其制备方法及含有其的药物组合物 |
CN102247350A (zh) * | 2011-05-23 | 2011-11-23 | 上海交通大学医学院附属瑞金医院 | 毛萼乙素在制备治疗自身免疫性疾病药物中的应用 |
CN110063949A (zh) * | 2019-05-14 | 2019-07-30 | 大连理工大学 | 王枣子乙素在制备用于治疗肺癌的药物中的用途 |
CN111363015A (zh) * | 2020-03-17 | 2020-07-03 | 江西省人民医院 | 分离提取细胞中浆蛋白和核蛋白的试剂、制备方法及应用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2473161T3 (en) * | 2009-08-31 | 2017-09-11 | Dr Reddys Laboratories Ltd | TOPICAL FORMULATIONS INCLUDING A STEROID |
CN102372724A (zh) * | 2010-08-26 | 2012-03-14 | 苏州宝泽堂医药科技有限公司 | 一种提取毛萼乙素的方法 |
EP3007686A4 (en) * | 2013-06-10 | 2017-03-15 | Yeda Research and Development Co., Ltd. | Compositions and methods for treating a hematological malignancy associated with an altered runx1 activity or expression |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1424028A (zh) * | 2002-11-21 | 2003-06-18 | 中国科学院昆明植物研究所 | 一种治疗癌症的药物及其用途 |
CN1486712A (zh) * | 2003-08-09 | 2004-04-07 | 北海国发海洋生物产业股份有限公司 | 中药冬凌草有效部位抗肿瘤药物提取物及其制备方法 |
CN1329083C (zh) * | 2004-03-11 | 2007-08-01 | 上海第二医科大学附属瑞金医院 | 一种降解aml1-eto融合蛋白的方法及所用试剂 |
CN100479815C (zh) * | 2004-03-11 | 2009-04-22 | 上海第二医科大学附属瑞金医院 | 一种治疗m2型急性髓性白血病的药物及其注射液的制备 |
-
2005
- 2005-11-07 CN CNB2005101100898A patent/CN100370981C/zh not_active Expired - Fee Related
-
2006
- 2006-10-08 US US12/092,914 patent/US20080300299A1/en not_active Abandoned
- 2006-10-08 JP JP2008539213A patent/JP2009514903A/ja active Pending
- 2006-10-08 EP EP06791205A patent/EP1952811A4/en not_active Withdrawn
- 2006-10-08 WO PCT/CN2006/002623 patent/WO2007051390A1/zh active Application Filing
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101318965B (zh) * | 2008-07-18 | 2010-11-24 | 中国科学院昆明植物研究所 | 毛萼乙素结晶、其制备方法及含有其的药物组合物 |
CN102247350A (zh) * | 2011-05-23 | 2011-11-23 | 上海交通大学医学院附属瑞金医院 | 毛萼乙素在制备治疗自身免疫性疾病药物中的应用 |
CN110063949A (zh) * | 2019-05-14 | 2019-07-30 | 大连理工大学 | 王枣子乙素在制备用于治疗肺癌的药物中的用途 |
CN111363015A (zh) * | 2020-03-17 | 2020-07-03 | 江西省人民医院 | 分离提取细胞中浆蛋白和核蛋白的试剂、制备方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100370981C (zh) | 2008-02-27 |
WO2007051390A1 (fr) | 2007-05-10 |
JP2009514903A (ja) | 2009-04-09 |
EP1952811A1 (en) | 2008-08-06 |
US20080300299A1 (en) | 2008-12-04 |
EP1952811A4 (en) | 2010-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wu et al. | Biologically synthesized green gold nanoparticles from Siberian ginseng induce growth-inhibitory effect on melanoma cells (B16) | |
Liu et al. | Shikonin induces apoptosis and prosurvival autophagy in human melanoma A375 cells via ROS-mediated ER stress and p38 pathways | |
Jiang et al. | Oridonin‐induced mitochondria‐dependent apoptosis in esophageal cancer cells by inhibiting PI3K/AKT/mTOR and Ras/Raf pathways | |
Shen et al. | Evaluation of the anti-inflammatory activity of zhankuic acids isolated from the fruiting bodies of Antrodia camphorata | |
Yang et al. | Autophagy is associated with apoptosis in cisplatin injury to renal tubular epithelial cells | |
CN1868468A (zh) | 毛萼乙素在制药中的应用 | |
Kuo et al. | Cantharidin induces apoptosis in human bladder cancer TSGH 8301 cells through mitochondria-dependent signal pathways | |
Feng et al. | Novel function of scutellarin in inhibiting cell proliferation and inducing cell apoptosis of human Burkitt lymphoma Namalwa cells | |
Wang et al. | Comparison of hepatotoxicity and mechanisms induced by triclosan (TCS) and methyl-triclosan (MTCS) in human liver hepatocellular HepG2 cells | |
Wang et al. | Brevilin A promotes oxidative stress and induces mitochondrial apoptosis in U87 glioblastoma cells | |
Lyu et al. | Cell-penetrating peptide conjugates of gambogic acid enhance the antitumor effect on human bladder cancer EJ cells through ROS-mediated apoptosis | |
Lee et al. | Phellinus linteus extract induces autophagy and synergizes with 5-fluorouracil to inhibit breast cancer cell growth | |
Scherbakov et al. | Antiestrogenic and antiproliferative potency of secoisolariciresinol diglucoside derivatives on MCF-7 breast cancer cells | |
Hadisaputri et al. | Caspase cascade activation during apoptotic cell death of human lung carcinoma cells A549 induced by marine sponge Callyspongia aerizusa | |
Li et al. | The effect of resveratrol, curcumin and quercetin combination on immuno-suppression of tumor microenvironment for breast tumor-bearing mice | |
Amini et al. | The p53 modulated cytotoxicity of ophiocoma scolopendrina polysaccharide against resistance ovarian cancer cells | |
Wang et al. | Preclinical evaluation on the tumor suppression efficiency and combination drug effects of fermented wheat germ extract in human ovarian carcinoma cells | |
Mahmoud et al. | Effects of silymarin and mesenchymal stem cells on hematological and some biochemical changes induced by gamma radiation in albino rats | |
CN1215070C (zh) | 前胡丙素在制备治疗肿瘤药物中的应用 | |
Hussein et al. | Evaluation of the anticancer effect of violacein, phycocyanin and phycocyanobilin on apoptotic genes expression and glycan profiles in breast cancer cells | |
CN1165301C (zh) | 组合物在制备治疗癌症的药物中的用途 | |
Rajan et al. | Saccharomyces cerevisiae-induced apoptosis of monolayer cervical cancer cells | |
Chou et al. | Involvement of p38 MAPK in the Anticancer Activity of Cultivated Cordyceps militaris | |
Muthiyan et al. | Antiproliferative and proapoptotic activities of marine sponge Hyrtios erectus extract on breast carcinoma cell line (MCF-7) | |
CN100346830C (zh) | 一种治疗b细胞淋巴瘤的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20061027 Address after: No. two, No. 197, Ruijin, Shanghai Applicant after: Affiliated Ruijin Hospital of Shanghai Second Medical University Co-applicant after: Kunming Institute of Botany, Chinese Academy of Sciences Address before: No. two, No. 197, Ruijin, Shanghai Applicant before: Affiliated Ruijin Hospital of Shanghai Second Medical University |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080227 Termination date: 20111107 |